Transaction Brings Together Groundbreaking Preclinical Assets and Outstanding Drug-Development Expertise
ST. LOUIS–(BUSINESS WIRE)–Antegrin Therapeutics and Cascadia Therapeutics today announced the formation of Indalo Therapeutics, a biotechnology company dedicated to developing novel therapies to treat fibrotic diseases. The entity results from the merger of Antegrin and Cascadia and the consolidation of their respective management teams. Financial terms of the deal were not disclosed.
Read the whole press release here.